Mark A Rizzo

Address:

9025 Gardenia Rd, Nottingham, MD 21236

Phone:

4105291993

VIN:

5NPET46C77H201784

Make:

HYUNDAI

Model:

SONATA

Year:

2007

US Patent:

7351537, Apr 1, 2008

Filed:

Sep 23, 2004

Appl. No.:

10/948846

Inventors:

David Piston - Nashville TN, US
Mark Rizzo - Nashville TN, US

Assignee:

Vanderbilt University - Nashville TN

International Classification:

C12Q 1/68
C12P 1/00
C12N 5/00
C07H 21/04
C07K 14/00

US Classification:

435 6, 435 41, 435 691, 435325, 435410, 536 231, 530350

Abstract:

The present invention provide optimized cyan fluorescent protein (oCFP) variants. In particular, the variants exhibit increase quantum yield of fluorescence and a single component fluorescence lifetime.

US Patent:

8031338, Oct 4, 2011

Filed:

Nov 30, 2005

Appl. No.:

11/291111

Inventors:

David Piston - Nashville TN, US
Mark Rizzo - Nottingham MD, US

Assignee:

Vanderbilt University - Nashville TN

International Classification:

G01J 3/447

US Classification:

356327

Abstract:

The present invention provides improved methods for assessing Förster resonance energy transfer using polarized light. Specifically, the methods rely on measuring depolarized light emitted by fluorescent acceptor molecules.

US Patent:

20050009129, Jan 13, 2005

Filed:

May 3, 2004

Appl. No.:

10/838167

Inventors:

Mark Rizzo - Nashville TN, US
David Piston - Nashville TN, US

International Classification:

C12Q001/48
C12N009/12
C07H021/04

US Classification:

435015000, 435069100, 435194000, 435320100, 435325000, 536023200

Abstract:

The present invention relates to providing novel therapeutics for treating diabetes other glycemic disorders. Such therapeutics involve the signaling pathways that contribute to regulation of glucose-stimulated insulin secretion. Of particular interest are modulators of a key component in the glucokinase pathway. Thus, the present provides methods of screening for modulators of glucokinase activity, expression, translocation, conformation, nitrosylation and interaction with other molecules as useful target for pharmacological manipulation in the treatment of diabetes and other glycemic disorders.

US Patent:

20160228502, Aug 11, 2016

Filed:

Feb 4, 2016

Appl. No.:

15/016086

Inventors:

- Baltimore MD, US
Robert J. Bloch - Baltimore MD, US
Mark A. Rizzo - Nottingham MD, US
Joaquin Muriel - New Freedom PA, US
Michele L. Markwardt - Baltimore MD, US

International Classification:

A61K 38/17
A61K 35/76
A61K 31/7105
A61K 35/761

Abstract:

Embodiments of the disclosure concern methods and compositions related to the small Ankyrin 1 (sAnk1) protein and its role as a regulatory protein in at least muscle cells. In particular embodiments, its expression and/or activity are modulated with one or more compositions. In specific embodiments, compositions such as nucleic acids that inhibit expression of sAnk1 are utilized for a variety of methods, whereas in other embodiments compositions such as polypeptides, peptides, or sAnk1-encoding nucleic acids that enhance sAnk1 levels are utilized for certain methods.